Editas Medicine sought regulatory feedback from the FDA on clinical trials and listed its shares on an exchange on May 27, 2026.
4 reports, 2 independent
Updated Aug 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Editas Medicine sought regulatory feedback from the FDA on clinical trials and listed its shares on an exchange on May 27, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Editas Medicine
discovery-phase pharmaceutical company
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
Related events
- InflaRx is seeking discussions with the FDA and collaborating with Staidson BioPharmaceuticals on clinical trials.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Arthur Caplan questioned the FDA regarding the status of clinical trials in 2006.
- Benchmark and Jefferies reaffirmed buy ratings while the FDA cited toxicity findings for Bright Minds Biosciences Inc.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.